MedPath

NYU LANGONE HEALTH

NYU LANGONE HEALTH logo
🇺🇸United States
Ownership
Private
Established
1841-01-01
Employees
10K
Market Cap
-
Website
http://www.nyulangone.org

Clinical Trials

1.3k

Active:51
Completed:751

Trial Phases

6 Phases

Early Phase 1:19
Phase 1:93
Phase 2:152
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1120 trials with phase data)• Click on a phase to view related trials

Not Applicable
712 (63.6%)
Phase 2
152 (13.6%)
Phase 4
110 (9.8%)
Phase 1
93 (8.3%)
Phase 3
34 (3.0%)
Early Phase 1
19 (1.7%)

Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

Recruiting
Conditions
Prostate Cancer
First Posted Date
2025-09-22
Last Posted Date
2025-09-22
Lead Sponsor
NYU Langone Health
Target Recruit Count
1000
Registration Number
NCT07184957
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative

Not Applicable
Not yet recruiting
Conditions
Cannabis Use Disorder
First Posted Date
2025-09-22
Last Posted Date
2025-09-22
Lead Sponsor
NYU Langone Health
Target Recruit Count
46
Registration Number
NCT07184983
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

Not yet recruiting
Conditions
Prostate Cancer
First Posted Date
2025-09-22
Last Posted Date
2025-09-22
Lead Sponsor
NYU Langone Health
Target Recruit Count
60
Registration Number
NCT07184970
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

Not Applicable
Recruiting
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Device: 89Zr-DFO-girentuximab PET
First Posted Date
2025-09-18
Last Posted Date
2025-09-23
Lead Sponsor
NYU Langone Health
Target Recruit Count
12
Registration Number
NCT07179770
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.

Not Applicable
Active, not recruiting
Conditions
Skin Cancer
First Posted Date
2025-09-17
Last Posted Date
2025-09-17
Lead Sponsor
NYU Langone Health
Target Recruit Count
45
Registration Number
NCT07177638
Locations
🇺🇸

Jewish Community House of Bensonhurst, Brooklyn, New York, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 266
  • Next

News

CAR-T Therapy Shows Unprecedented Promise as Potential Cure for Lupus in Early Clinical Trials

Early phase clinical trials of CAR-T cellular therapy for systemic lupus erythematosus are showing unprecedented results, with patients experiencing quick resolution of clinical and laboratory abnormalities.

SurgiVance Secures $2.2M NIH Grant to Advance Direct-to-Digital Pathology Platform

SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology.

Experimental CoQ10 Precursor Treatment Shows Dramatic Results in 8-Year-Old with Rare Fatal Disease

An 8-year-old boy with HPDL deficiency, a rare mitochondrial disease causing paralysis and often death, showed dramatic improvement after receiving an experimental treatment with 4-hydroxybenzoate (4-HB).

Novel Bispecific Antibody Shows Promise for Autoimmune Disease Treatment in Preclinical Studies

Researchers at NYU Langone Health developed a bispecific antibody called BiTS that targets both T cell receptors and LAG-3 checkpoints to selectively suppress autoimmune T cells.

Mitochondrial DNA Variant Predicts Immunotherapy Resistance in Metastatic Melanoma

Researchers analyzed genetic material from 1,225 metastatic melanoma patients and identified that those with mitochondrial haplogroup T (HG-T) were 3.46 times less likely to respond to checkpoint inhibitor therapy.

URO-1's SUREcore Biopsy System Shows Significant Improvement in Prostate Cancer Diagnostic Accuracy

URO-1's SUREcore biopsy needle demonstrated 92% targeting accuracy compared to 36% for standard needles, representing a major advancement in prostate cancer diagnostics.

ctDNA Monitoring Shows Promise for Predicting Melanoma Recurrence After Surgery

Circulating tumor DNA (ctDNA) monitoring can reliably identify minimal residual disease in patients with resected stage III melanoma, predicting high risk of early recurrence even when patients appear disease-free by radiographic measures.

Ultra-Rapid Genetic Test Revolutionizes Brain Cancer Surgery with Real-Time Tumor Detection

A new Ultra-Rapid droplet digital PCR test can detect brain cancer cells in tissue samples within 15 minutes, providing surgeons with real-time feedback during operations.

BRCA2 Mechanism Reveals Why PARP Inhibitors Work in Only Some Cancer Patients

NYU Langone researchers have discovered that BRCA2 acts as a molecular shield preventing PARP1 from binding to DNA damage sites, explaining why PARP inhibitors are effective only in certain cancer patients.

Nutrition's Critical Role in Cancer Care: From Prevention to Survivorship

Nutrition plays a vital role throughout the cancer journey, with different dietary strategies needed during active treatment versus survivorship and prevention phases.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.